US EditionPublished • loading... • Updated
Novo Nordisk Canada considers competing with generics through renamed lower-price Ozempic
Novo Nordisk launches Plosbrio and Poviztra to compete with generics, aiming to improve affordability for over one million Canadian patients using semaglutide drugs.
- Novo Nordisk Canada is considering introducing renamed, lower-priced copies of its drugs Ozempic and Wegovy, called Plosbrio and Poviztra, to compete with generic versions once they enter the Canadian market.
- Health Canada has approved nine submissions from other drug companies to make generic versions of the active ingredient semaglutide, but the review process is complex due to potential differences in safety and efficacy.
- Pharmaceutical policy expert Mina Tadrous called Novo Nordisk's potential move 'an interesting play' to stay competitive, as they cannot lower the price of their brand-name products to allow generic market entry.
Insights by Ground AI
Podcasts & Opinions
28 Articles
28 Articles
NiagaraFallsReview.ca+25 Reposted by 25 other sources
Novo Nordisk considers competing with generics through renamed lower-price Ozempic
TORONTO - Novo Nordisk Canada is considering competing with generic versions of its brand-name Ozempic and Wegovy drugs by introducing renamed, lower-priced copies of the medications.
·Niagara Falls, Canada
Read Full Article
Canada moves toward generic Ozempic, but approvals and pricing remain uncertain
OTTAWA — Canada is edging closer to cheaper versions of Ozempic and Wegovy, though patients are unlikely to see immediate price relief as Health Canada continues to review multiple generic drug submissions and Novo Nordisk moves to protect its market share. The federal regulator has received nine applications from several companies seeking approval to sell generic versions of semaglutide, the active ingredient in the blockbuster diabetes and wei…
Coverage Details
Total News Sources28
Leaning Left16Leaning Right1Center4Last UpdatedBias Distribution76% Left
Bias Distribution
- 76% of the sources lean Left
76% Left
L 76%
C 19%
Factuality
To view factuality data please Upgrade to Premium
